Cargando…

The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population

BACKGROUND: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COP...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Xia, Murphy, Michael J, MacDonald, Thomas M, Wei, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490740/
https://www.ncbi.nlm.nih.gov/pubmed/22935195
http://dx.doi.org/10.1186/1471-2458-12-712
_version_ 1782248861656416256
author Sheng, Xia
Murphy, Michael J
MacDonald, Thomas M
Wei, Li
author_facet Sheng, Xia
Murphy, Michael J
MacDonald, Thomas M
Wei, Li
author_sort Sheng, Xia
collection PubMed
description BACKGROUND: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COPD), osteoarthritis (OA), rheumatoid arthritis (RA), chronic kidney disease (CKD), and diabetes mellitus (DM)) and to compare effectiveness with the rest of the population not recorded as having these diseases. METHODS: A population-based cohort study was conducted in Tayside population who had at least two TC measurements between 1993 and 2007. There were 12,140 patients with chronic diseases and 9,481 patients in the rest of the population not recorded as having these chronic diseases. The main outcomes were TC change from baseline, CV events and all-cause mortality. RESULTS: Statin-associated TC reductions varied from 15% to 28% with baseline value of between 5.1 and 5.9 mmol/L in the primary prevention (PP) and from 7% to 23% with baseline value of 4.5 to 5.2 mmol/L in the secondary prevention (SP) among chronic diseases patients. In the rest of the population, TC reductions with statins were 31% in PP and 28% in SP with baselines of 6.3 mmol/L and 5.3 mmol/L, respectively (test of heterogeneity with chronic disease groups: p < 0.001). A notional reduction of 0.5 mmol/L in TC predicted variable reductions in incident CV events of 30% in RA, 19% in CKD, and 20% in DM, and recurrent CV events by 62% in COPD, 16% in CKD, and 19% in DM. The corresponding figures for the rest of population were 12% for incident CV events and 17% for the recurrent CV events, respectively. Risk reductions for all-cause mortality varied from 20% to 36% in PP and from 18% to 40% in SP, except in OA or RA patients in the chronic diseases and 11% in PP and 16% in the rest of population (test of heterogeneity: p > 0.05). CONCLUSIONS: The effectiveness of statins in common chronic diseases varied. With the exception of diabetes, statins tends to be less effective in patients with the chronic diseases compared with the rest of the study population. Changes in TC with statins appear not to correlate well with the changes in cardiovascular events and all-cause mortality.
format Online
Article
Text
id pubmed-3490740
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34907402012-11-07 The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population Sheng, Xia Murphy, Michael J MacDonald, Thomas M Wei, Li BMC Public Health Research Article BACKGROUND: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COPD), osteoarthritis (OA), rheumatoid arthritis (RA), chronic kidney disease (CKD), and diabetes mellitus (DM)) and to compare effectiveness with the rest of the population not recorded as having these diseases. METHODS: A population-based cohort study was conducted in Tayside population who had at least two TC measurements between 1993 and 2007. There were 12,140 patients with chronic diseases and 9,481 patients in the rest of the population not recorded as having these chronic diseases. The main outcomes were TC change from baseline, CV events and all-cause mortality. RESULTS: Statin-associated TC reductions varied from 15% to 28% with baseline value of between 5.1 and 5.9 mmol/L in the primary prevention (PP) and from 7% to 23% with baseline value of 4.5 to 5.2 mmol/L in the secondary prevention (SP) among chronic diseases patients. In the rest of the population, TC reductions with statins were 31% in PP and 28% in SP with baselines of 6.3 mmol/L and 5.3 mmol/L, respectively (test of heterogeneity with chronic disease groups: p < 0.001). A notional reduction of 0.5 mmol/L in TC predicted variable reductions in incident CV events of 30% in RA, 19% in CKD, and 20% in DM, and recurrent CV events by 62% in COPD, 16% in CKD, and 19% in DM. The corresponding figures for the rest of population were 12% for incident CV events and 17% for the recurrent CV events, respectively. Risk reductions for all-cause mortality varied from 20% to 36% in PP and from 18% to 40% in SP, except in OA or RA patients in the chronic diseases and 11% in PP and 16% in the rest of population (test of heterogeneity: p > 0.05). CONCLUSIONS: The effectiveness of statins in common chronic diseases varied. With the exception of diabetes, statins tends to be less effective in patients with the chronic diseases compared with the rest of the study population. Changes in TC with statins appear not to correlate well with the changes in cardiovascular events and all-cause mortality. BioMed Central 2012-08-30 /pmc/articles/PMC3490740/ /pubmed/22935195 http://dx.doi.org/10.1186/1471-2458-12-712 Text en Copyright ©2012 Sheng et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sheng, Xia
Murphy, Michael J
MacDonald, Thomas M
Wei, Li
The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
title The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
title_full The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
title_fullStr The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
title_full_unstemmed The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
title_short The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
title_sort comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490740/
https://www.ncbi.nlm.nih.gov/pubmed/22935195
http://dx.doi.org/10.1186/1471-2458-12-712
work_keys_str_mv AT shengxia thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT murphymichaelj thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT macdonaldthomasm thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT weili thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT shengxia comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT murphymichaelj comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT macdonaldthomasm comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation
AT weili comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation